E Dovern B J Biemond E Nur
10.3389/fimmu.2023.1212007
Front Immunol
2023 Jun 23;14:1212007.
daratumumab (dara) hematopoietic (stem) cell transplantation (hcst) mixed chimerism pure red cell aplasia (prca) sickle cell disease
CC BY
https://pubmed.ncbi.nlm.nih.gov/37426651/
Anemia, Sickle Cell / complications Anemia, Sickle Cell / therapy Hematopoietic Stem Cell Transplantation / adverse effects Red-Cell Aplasia, Pure / drug therapy Red-Cell Aplasia, Pure / etiology
Anemia, Sickle Cell / complications Anemia, Sickle Cell / therapy Hematopoietic Stem Cell Transplantation / adverse effects Red-Cell Aplasia, Pure / drug therapy Red-Cell Aplasia, Pure / etiology Case Reports Adult Antibodies, Monoclonal / therapeutic use Chimerism Hemagglutinins Humans daratumumab Hemagglutinins Antibodies, Monoclonal
PMC10326381
37426651
Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease
2023